Table 3.

Estimated differences in median Shedding Index Endpoint (SIE) across the quantifiable range of pre-challenge type 2 neutralizing antibody titers (value at LLOQ minus value at ULOQ) for the subset analysis of IPV001-only participants. Randomization to regimen was balanced across country, and all subjects received three doses of bOPV, and 0, 1, or 2 doses of IPV.

Country (n subjects)	Estimated median difference in SIE (95% CI)
Colombia (191)	1.42 (0.04, 2.81)
Dominican Republic (424)	0.95 (−0.22, 2.11)
Guatemala (111)	1.64 (0.33, 2.95)
Panama (433)	1.17 (0.22, 2.12)